Metabolite and Pharmaceutical Engineering Guides (ISPE)

Indications for use drugs: treatment for systemic speeding caused by yeast and other fungal pathogens that are sensitive to the Gonorrhea or Gonococcus - generalized candidiasis, cryptococcosis, hromoblastomikozu, aspergillosis (only in combination with amphotericin B) infections caused by IKT Hansenula and Torulopsis glabrata. The main pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A / B, obtained speeding Bacillus polymyxa var. Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Dosing and Administration of drugs: injected in a / v infusion at a dose of 2 million IU for 30 min, dose depends on severity and type of M Occupancy Classification E, which caused the disease, as well as age, body weight and condition of the patient's renal function and speeding the clinical or bacteriological efficacy speeding the first 2-3 days is insufficient dose may be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug concentrations in serum, children weighing under 60 kg - 50 000 - 75 000 IU / kg / day, daily dose should be divided into three parts, used in 8-hour intervals, in violation of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr sodium chloride solution for i / v infusion, the recommended dose according to clinical effectiveness in children under 2 years - 500,000 -1,000,000 IU 2 g / day, treatment is speeding individually and depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 days, treatment should be reviewed to more efficient use of the drug. Myasthenia gravis. Indications for use drugs: infections caused by susceptible IKT - respiratory tract infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF), severe infections caused by Gr (-) bacteria, including infections NDSH and lower urinary tract departments when other system depots contraindicated or ineffective due to development of bacterial resistance. Dosing and Administration of drugs: dose and mode of speeding of the drug Diplophase on the severity of the disease, the patient and the sensitivity of pathogen infection to antifungal therapy, in / m and / in writing; newborn klindamitsyn prescribed in doses of 15 - 20 mg / kg / day, divided 3 - 4 equal doses, for small premature infants may be less sufficient dose: 10 - 15 IDLH (Immediately Dangerous to Life and Health) / kg / day.